Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balloon Elution and Late Loss Optimization (BELLO) Study: A Multicentre Randomized Study of the IN.PACT Falcon Paclitaxel Drug-eluting Balloon to Reduce Restenosis in Small Coronary Vessels.

Trial Profile

Balloon Elution and Late Loss Optimization (BELLO) Study: A Multicentre Randomized Study of the IN.PACT Falcon Paclitaxel Drug-eluting Balloon to Reduce Restenosis in Small Coronary Vessels.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemia; Unstable angina pectoris
  • Focus Biomarker; Therapeutic Use
  • Acronyms BELLO
  • Most Recent Events

    • 14 Aug 2013 Biomarkers information updated
    • 02 Nov 2012 Primary endpoint 'Late-loss' has been met.
    • 29 May 2012 Planned End Date changed from 1 Sep 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top